Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen

TD Cowen upgraded shares of Keros Therapeutics (NASDAQ:KROS) to a hold rating in a report published on Friday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. Wedbush raised their target price on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Wells Fargo & Company lowered their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Bank of America increased their target price on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.38.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $20.26 on Friday. The company has a market capitalization of $617.32 million, a PE ratio of 13.16, a price-to-earnings-growth ratio of 0.25 and a beta of 0.89. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $22.55. The firm has a 50 day moving average price of $17.36 and a 200 day moving average price of $15.61.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The company had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. During the same period in the prior year, the firm earned ($1.41) earnings per share. The firm’s revenue was up 3585.6% compared to the same quarter last year. As a group, equities research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently bought and sold shares of KROS. Vanguard Group Inc. increased its position in Keros Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after buying an additional 87,129 shares during the period. Western Standard LLC increased its holdings in shares of Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after acquiring an additional 654,989 shares during the period. ADAR1 Capital Management LLC raised its position in Keros Therapeutics by 6,294.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after purchasing an additional 1,463,215 shares during the last quarter. Geode Capital Management LLC boosted its stake in Keros Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 829,297 shares of the company’s stock worth $11,073,000 after purchasing an additional 23,112 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.